Advertisement

The impact of sociodemographic characteristics on diagnosis and access to disease-modifying treatment for patients with multiple sclerosis in Morocco

Published:September 23, 2022DOI:https://doi.org/10.1016/j.msard.2022.104193

      Highlights

      • Sociodemographic characteristics of patients with multiple sclerosis in morocco.
      • The majority of patients with multiple sclerosis have no healthcare coverage.
      • Most of the patients surveyed did not have access to disease-modifying treatment.
      • Diagnosis and access to treatment are closely linked to certain sociodemographic factors.
      • In Morocco, the diagnosis of multiple sclerosis is delayed.

      Abstract

      Objective

      This study aims to determine the link between sociodemographic factors, diagnosis, and access to disease-modifying treatment for patients with multiple sclerosis (MS) in Morocco.

      Methods

      This study concerned a sample of 520 patients representing seven regions of Morocco. We obtained data from the patient record registers, the patient's files, and a questionnaire.

      Results

      The results showed female dominance (69.4%) in patients with MS (69.4%). Besides, patients with this disease are generally young; their mean age is 35.36. The employment rate among the surveyed population was 24.9%. More than 74.6% have no health care coverage, and 70.4% of the patients investigated live without treatment. The results show a significant association between access to treatment and several sociodemographic factors, such as the patient's job, health care coverage, region, and marital status. There is also a link between these sociodemographic factors and access to diagnosis.

      Conclusions

      Diagnosis and access to treatment are associated with certain sociodemographic factors such as health insurance coverage, the patient's job, regional belonging, and marital status.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aires A.
        • Barros A.
        • Machado C.
        • Fitas D.
        • Cação G.
        • Pedrosa R.
        • Cerqueira J.
        • Perdigão S.
        • Silva A.M.
        • Vale J.
        • Sá M.J.
        • Andrade C.
        Diagnostic delay of multiple sclerosis in a Portuguese population.
        Acta Med. Port. 2019; 32: 289-294https://doi.org/10.20344/amp.11187
        • Barin L.
        • Kamm C.P.
        • Salmen A.
        • Dressel H.
        • Calabrese P.
        • Pot C.
        • Schippling S.
        • Gobbi C.
        • Müller S.
        • Chan A.
        • Rodgers S.
        • Kaufmann M.
        • Ajdacic-Gross V.
        • Steinemann N.
        • Kesselring J.
        • Puhan M.A.
        • von Wyl V.
        How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
        Mult. Scler. 2020; 26: 489-500https://doi.org/10.1177/1352458518823955
        • Béneton C.
        • Rumbach L.
        [Social and economic impact of multiple sclerosis].
        Rev. Prat. 1999; 49: 1890-1893
        • Calocer F.
        • Dejardin O.
        • Kwiatkowski A.
        • Bourre B.
        • Vermersch P.
        • Hautecoeur P.
        • Launoy G.
        • Defer G.
        Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients.
        Mult. Scler. Relat. Disord. 2020; 40101930https://doi.org/10.1016/j.msard.2020.101930
        • Cambier-Langrand E.
        • Leroyer A.
        • Zéphir H.
        • Fernandes C.
        • Jougleux C.
        • Cabaret M.
        • Vermersch P.
        • Fantoni-Quinton S.
        Impact socioprofessionnel précoce de la sclérose en plaques : une étude prospective d'une série de 24 patients.
        Archives des Maladies Professionnelles et de l'Environnement. 2016; 77: 165-178https://doi.org/10.1016/j.admp.2015.09.004
        • Cárdenas-Robledo S.
        • Lopez-Reyes L.
        • Arenas-Vargas L.E.
        • Carvajal-Parra M.S.
        • Guío-Sánchez C.
        Delayed diagnosis of multiple sclerosis in a low prevalence country.
        Neurolog. Res. 2021; 43: 521-527https://doi.org/10.1080/01616412.2020.1866374
      1. Charil, A., Yousry, T.A., Rovaris, M., Barkhof, F., Stefano, N.D., Fazekas, F., Miller, D.H., Montalban, X., Simon, J.H., Polman, C., & Filippi, M. (2006). MRI and the diagnosis of multiple sclerosis : Expanding the concept of “no better explanation”. 12.

        • Douma R.
        • Hassine A.
        • Zouari N.
        • Ben Amor S.
        • Salma N.
        • Soufien B.A.
        Statut professionnel au cours de la sclérose en plaques.
        Rev. Neurol. (Paris). 2018; 174: S103https://doi.org/10.1016/j.neurol.2018.01.233
        • Fernández O.
        • Fernández V.
        • Arbizu T.
        • Izquierdo G.
        • Bosca I.
        • Arroyo R.
        • García Merino J.A.
        • de Ramón E.
        • The Novo Group
        Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study).
        J. Neurol. 2010; 257: 1500-1507https://doi.org/10.1007/s00415-010-5560-1
      2. Flemmen, H. (2019). Socioeconomic factors as predictors for ms susceptibility and disease progression—Validation of a new norwegian questionnaire. https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279125/.

        • Flemmen H.Ø.
        • Simonsen C.S.
        • Broch L.
        • Brunborg C.
        • Berg-Hansen P.
        • Moen S.M.
        • Kersten H.
        • Celius E.G.
        The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort.
        Mult. Scler. Relat. Disord. 2022; 61https://doi.org/10.1016/j.msard.2022.103759
        • Gharibi F.
        • Imani A.
        • Koustuv D.
        The catastrophic out-of-pocket health expenditure of multiple sclerosis patients in Iran.
        BMC Health Services Res. 2021; 21 (Article): 1https://doi.org/10.1186/s12913-021-06251-4
        • Ghiasian M.
        • Faryadras M.
        • Mansour M.
        • Khanlarzadeh E.
        • Mazaheri S.
        Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990-2016.
        Acta Neurologica. Belgica. 2021; 121: 199-204https://doi.org/10.1007/s13760-020-01528-7
        • Ghiasian M.
        • Faryadras M.
        • Mansour M.
        • Khanlarzadeh E.
        • Mazaheri S.
        Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990-2016.
        Acta Neurologica.. Belgica. 2021; 121: 199-204https://doi.org/10.1007/s13760-020-01528-7
        • Harding K.E.
        • Wardle M.
        • Carruthers R.
        • Robertson N.
        • Zhu F.
        • Kingwell E.
        • Tremlett H.
        Socioeconomic status and disability progression in multiple sclerosis : a multinational study.
        Neurology. 2019; 92: e1497-e1506https://doi.org/10.1212/WNL.0000000000007190
      3. HCP. (2021a). Note d'information du Haut-Commissariat au Plan relative aux principales caractéristiques de la population active occupée en 2021 (p. 7). Haut commissariat au plan. https://www.hcp.ma/Note-D-information-du-haut-commissariat-au-plan-relative-aux-principales-caracteristiques-de-la-population-active_a2825.html.

      4. HCP. (2021b). Note d'information du Haut-Commissariat au Plan relative aux principales caractéristiques de la population active occupée en 2021 (p. 7). Haut commissariat au plan. https://www.hcp.ma/Note-D-information-du-haut-commissariat-au-plan-relative-aux-principales-caracteristiques-de-la-population-active_a2825.html.

        • Hirsch E.C.
        Inflammatory Changes and Apoptosis in Parkinson's Disease.
        (Éds)in: Mizuno Y. Fisher A. Hanin I. Mapping the Progress of Alzheimer's and Parkinson's Disease. Springer, US2002: 259-263https://doi.org/10.1007/978-0-306-47593-1_43
        • Kornblith A.
        • La Rocca N.
        • Baum H.
        Employment in individuals with multiple sclerosis.
        Int. J. Rehabil. Res.. Internationale Zeitschrift Fur Rehabilitationsforschung. Revue Internationale de Recherches de Readaptation. 1986; 9 (Article): 2https://doi.org/10.1097/00004356-198606000-00006
      5. Lassmann, H. (2018). Multiple Sclerosis Pathology. Cold Spring Harbor Laboratory Press.

        • Lavorgna L.
        • Borriello G.
        • Esposito S.
        • Abbadessa G.
        • Capuano R.
        • De Giglio L.
        • Logoteta A.
        • Pozzilli C.
        • Tedeschi G.
        • Bonavita S.
        Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online.
        Mult. Scler. Related Disor. 2019; 27: 239-246https://doi.org/10.1016/j.msard.2018.10.113
        • Mackenbach J.P.
        • Valverde J.R.
        • Artnik B.
        • Bopp M.
        • Brønnum-Hansen H.
        • Deboosere P.
        • Kalediene R.
        • Kovács K.
        • Leinsalu M.
        • Martikainen P.
        • Menvielle G.
        • Regidor E.
        • Rychtaříková J.
        • Rodriguez-Sanz M.
        • Vineis P.
        • White C.
        • Wojtyniak B.
        • Hu Y.
        • Nusselder W.J.
        Trends in health inequalities in 27 European countries.
        Proc. National Acad. Sci. 2018; 115: 6440-6445https://doi.org/10.1073/pnas.1800028115
        • McGinley M.P.
        • Goldschmidt C.H.
        • Rae-Grant A.D
        Diagnosis and treatment of multiple sclerosis : a review.
        JAMA. 2021; 325: 765-779https://doi.org/10.1001/jama.2020.26858
        • Minden S.L.
        • Hoaglin D.C.
        • Hadden L.
        • Frankel D.
        • Robbins T.
        • Perloff J.
        Access to and utilization of neurologists by people with multiple sclerosis.
        Neurology. 2008; 70: 1141-1149https://doi.org/10.1212/01.wnl.0000306411.46934.ef
        • Minden S.L.
        • Hoaglin D.C.
        • Hadden L.
        • Frankel D.
        • Robbins T.
        • Perloff J.
        Access to and utilization of neurologists by people with multiple sclerosis.
        Neurology. 2008; 70: 1141-1149https://doi.org/10.1212/01.wnl.0000306411.46934.ef
        • Mobasheri F.
        • Jaberi A.R.
        • Hasanzadeh J.
        • Fararouei M.
        Multiple sclerosis diagnosis delay and its associated factors among Iranian patients.
        Clin. Neurol. Neurosurg. 2020; 199106278https://doi.org/10.1016/j.clineuro.2020.106278
      6. Morocan ministry of health. (2019a). Health in figures 2019 (p. 121). Morocan ministry of health. https://www.sante.gov.ma/Documents/2021/12/Sante%20en%20chiffres%202019%20.pdf.

      7. Morocan ministry of health. (2019b). Health in figures 2019 (p. 121). Morocan ministry of health. https://www.sante.gov.ma/Documents/2021/12/Sante%20en%20chiffres%202019%20.pdf.

      8. Multiple Sclerosis International Federation. (2020). Clinical Management of Multiple Sclerosis Around the world, Key Finding About the Diagnosis and Clinical Management of MS (3rd Edition; p. 45).

      9. Multiple Sclerosis International Federation. (2021). MS Treatments and Therapies. MS International Federation. https://www.msif.org/living-with-ms/treatments/?lang=en/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/.

      10. Multiple Sclerosis International Federation, Atlas of MS. (2020a). Mapping multiple sclerosis around the world key epidemiology findings (3rd Edition). https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf.

      11. Multiple Sclerosis International Federation, Atlas of MS. (2020b). Morocco—Atlas of MS. https://www.atlasofms.org/fact-sheet/morocco.

      12. Multiple Sclerosis Society. (2019). Disease modifying therapies booklet. https://www.mssociety.org.uk/care-and-support/resources-and-publications/publications-search/disease-modifying-therapies-booklet.

      13. OECD. (2022). Employment rate (indicator). https://doi.org/OECD (2022), Employment Rate . doi: 10.1787/1de68a9b-en10.1787/1de68a9b-en (Accessed on 30 July 2022).

        • Poudel N.
        • Banjara B.
        • Kamau S.
        • Frost N.
        • Ngorsuraches S.
        Factors influencing patients’ willingness-to-pay for disease-modifying therapies for multiple sclerosis.
        Mul. Scler. Related Disor. 2021; 48102720https://doi.org/10.1016/j.msard.2020.102720
        • Poudel N.
        • Banjara B.
        • Kamau S.
        • Frost N.
        • Ngorsuraches S.
        Factors influencing patients’ willingness-to-pay for disease-modifying therapies for multiple sclerosis.
        Mul. Scler. Related Disor. 2021; 48102720https://doi.org/10.1016/j.msard.2020.102720
        • Raymond M.J.
        • Ray P.
        • Kaur G.
        • Fredericks M.
        • Singh A.V.
        • Wan L.Q.
        Multiaxial polarity determines individual cellular and nuclear chirality.
        Cellul. Molecular Bioengin. 2017; 10: 63-74https://doi.org/10.1007/s12195-016-0467-2
        • Roessler R.T.
        • Rumrill P.D.
        Multiple sclerosis and employment barriers : a systemic perspective on diagnosis and intervention.
        Work. 2003; 21: 17-23
        • Simacek K.F.
        • Ko J.J.
        • Moreton D.
        • Varga S.
        • Johnson K.
        • Katic B.J.
        The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis : mixed-Methods Study.
        J. Med. Internet Res. 2018; 20: e11168https://doi.org/10.2196/11168
        • Souliotis K.
        • Alexopoulou E.
        • Papageorgiou M.
        • Politi A.
        • Litsa P.
        • ContiadesX X.
        Access to care for multiple sclerosis in times of economic crisis in greece—The hope II study.
        Int. J. Health Policy Manag. 2015; 5https://doi.org/10.15171/ijhpm.2015.173
        • Souliotis K.
        • Alexopoulou E.
        • Papageorgiou M.
        • Politi A.
        • Litsa P.
        • ContiadesX X.
        Access to care for multiple sclerosis in times of economic crisis in Greece—The HOPE II study.
        Int. J. Health Policy Manag. 2015; 5 (Article): 2https://doi.org/10.15171/ijhpm.2015.173
        • Steenhof M.
        • Stenager E.
        • Nielsen N.M.
        • Kyvik K.
        • Möller S.
        • Hertz J.M.
        Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases.
        Mult. Scler. Related Disor. 2019; 32: 97-102https://doi.org/10.1016/j.msard.2019.04.012
      14. World Health Organization. (2017). Human rights and health. https://www.who.int/news-room/fact-sheets/detail/human-rights-and-health.

        • Yamout B.
        • Sahraian M.
        • Bohlega S.
        • Al-Jumah M.
        • Goueider R.
        • Dahdaleh M.
        • Inshasi J.
        • Hashem S.
        • Alsharoqi I.
        • Khoury S.
        • Alkhawajah M.
        • Koussa S.
        • Al Khaburi J.
        • Almahdawi A.
        • Alsaadi T.
        • Slassi E.
        • Daodi S.
        • Zakaria M.
        • Alroughani R.
        Consensus recommendations for the diagnosis and treatment of multiple sclerosis : 2019 revisions to the MENACTRIMS guidelines.
        Mult. Scler. Related Disor. 2020; 37101459https://doi.org/10.1016/j.msard.2019.101459